Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

"* 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart.~* 30-66 Gy in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart.~* 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques"

Tremelimumab 300 mg will be administered as an IV infusion for one dose

Treatment Duration Guidelines: \* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years. \* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years. \* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses.